Drugs / NVX-CoV2515
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05372588 | May → Jul 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVX-CoV2515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05372588 ↗ |
| Modality | Vaccine | “Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccines” NCT05372588 ↗ |
| Route | Intramuscular | “Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).” NCT05372588 ↗ |